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ABSTRACT
Heparanase (HPSE-1) is an endo-β-D-glucuronidase that cleaves heparan sulfate chains
of proteoglycans (HSPG), and its expression has been associated with increased growth,
mutations, and angiogenesis of tumors. Because metastatic melanoma cells express high levels
of HSPG, and their tumors grow highly vascularized, we analyzed HPSE-1 expression in vivo by
analyzing both experimental animals as well as clinical specimens with metastatic melanoma.
Laser capture microdissection microscopy was used to isolate and extract melanoma cell
populations from normal tissue. There was a 29-fold upregulation of heparanase expression,
detected by real-time PCR, by metastatic melanoma cell populations compared to normal lung
tissue in experimental animals. Additionally, immunohistochemistry (IHC) revealed a selective
HPSE-1 staining in human metastatic melanoma when compared to primary melanoma tumors.
IHC also showed a marked staining for HPSE-1 around blood vessels and vascular regions.
Finally, we developed an orthotopic brain slice model that should aid in the study of brain cancer
metastasis. This model allows for the characterization of tumor invasion at both quantitative
and qualitative levels. Brain-metastatic melanoma cells when treated with HPSE-1 versus
untreated cells showed a significant increase in the number of cells that invaded. Secondly,
melanoma cells, showed increasing HPSE-1 protein expression during a time course experiment.
We concluded that HPSE-1 expression likely plays important roles in regulating the growth and
progression of melanoma. These results also further emphasize the potential importance of
therapies designed to block HPSE-1 activity in controlling this type of cancer.
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CHAPTER 1: INTRODUCTION
Cancer is the second leading cause of death, and is a major health concern in the United
States and in the world. Cancer metastasis, which is the spread of tumor cells from a primary site
of origin to distant organs within the body, is a particularly important area in neoplasia as it
accounts for 90% of cancer related mortalities (Bogenrieder et al., 2003). The brain is one of
several highly targeted areas for metastatic cancers, and one of the highest frequencies of brain
metastases is found in malignant melanoma (Graf et al., 1988). Malignant melanoma has the
unfortunate distinction of being the cancer type with the highest increase in frequency of
occurrence, especially among young adults. Mechanisms responsible for melanoma progression
to highly aggressive metastatic disease are not fully understood (Bogenrieder et al., 2003)
Although metastatic mechanisms are not completely known, it has been demonstrated
that metastasis is not a random event. Rather, it is the result of a complex sequence of events that
occurs between normal host cells, tissues, and malignant cells (Bogenrieder et al., 2003;
Nakajima et al., 1988). Notably, all cells that metastasize must intravasate from the primary
tumor site into the blood vessels, circulate through the blood, attach to vessel walls, exit the
vasculature, and grow in the new surrounding tissue (Nicolson, 1982). During the metastatic
process, invading tumor cells must have the ability to breach tissue barriers. Degrading barriers
such as basement membranes, extracellular matrices (ECM), and connective tissue is dependent
on proteolytic enzymes such as heparanase (Nakajima et al., 1988).
One of the main components of the ECM are heparan sulfate proteoglycans (HSPGs), and
macromolecules composed of a core protein with heparan sulfate chains (HS) covalently
attached to it. These proteoglycans are ubiquitous in the ECM and as cell surface molecules
anchored into the plasma membrane. Recently, it has become increasingly clear that heparan
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sulfate (HS) and heparan sulfate proteoglycans (HSPGs) play important roles in promoting tumor
growth and metastasis. The main focus of this project was based on tumor invasiveness by the
action of heparanase (HPSE-1), an enzyme, which plays a central role in tumor progression by
releasing angiogenic molecules within the ECM resulting from the degradation of HSPGs.
HPSE-1 is a recently cloned enzyme, the first and only example of purification and cloning of a
mammalian HS degrading enzyme (Hulett et al., 1999; Kussie et al., 1999; Toyoshima et al.,
1999; Vlodavsky et al., 1999). HPSE-1 is involved in the degradation of the cell surface and
ECM (Bernfield et al., 1999; Iozzo, 1998; Iozzo, 2001; Rapraeger, 1995; Sanderson, 2001).
HPSE-1 is an endo-β-D-glucuronidase which cleaves heparan sulfate proteoglycans (HSPG).
HPSE-1 has significant regulatory consequences in cancer metastasis, and its expression has
been associated with increased growth, metastasis, and angiogenesis of tumors (Vlodavsky et al.,
2001).
The objective of this project was to establish 1) the expression and functionality of
HPSE-1 in malignant melanoma in vivo, and 2) to develop an organotypic culture system that
may be useful in studying the process of brain-metastatic melanoma invasion. This model
provides a better representation than the currently available model systems of the ECM
molecules normally encountered by invading melanoma cells. This brain slice model gives the
ability to monitor tumor invasion at both quantitative and qualitative levels. For example, similar
orthotopic brain slice models are currently being used as invasion assays for glioma cells and
monitoring dendrite development (Nakada et al., 2004; Salama-Cohen et al., 2005)
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CHAPTER 2: LITERATURE REVIEW
2.1 Historical Overview
Metastasis, which is the spread of cancer cells that have originated from a primary tumor
of origin to distant loci throughout the body, is a major area of interest within the cancer research
field. The reason for this high degree of interest resides in the fact that metastasis is the leading
cause of cancer related mortalities. Cancer metastasis accounts for 90% of the deaths of a disease
that is the second leading cause of death in the United States. This makes understanding the
metastatic process at the systemic, cellular, and molecular levels important goals of cancer
research (Bogenrieder et al., 2003; Marchetti et al., 2003a).
Over 130 years ago, Stephen Paget published the ‘seed and soil’ hypothesis as an
explanation for non-random patterns of metastatic development. This hypothesis has stood the
test of time and is still one of two main models for the patterns of metastasis. Paget’s hypothesis
was centralized around the idea that metastasis was not due to chance. Instead it was the result of
certain tumor cells (Paget called them the “seed”) that had an affinity for certain organs (Paget
related as the “soil”). His model was that metastasis formation is dependent upon both “the seed
and the soil” being compatible (Fidler et al., 2002).
The other model for the spread of malignancy, proposed by James Ewing in 1932, states
that metastasis occurs solely by a mechanical process. He stated that metastasis was the result of
anatomical and hemodynamic factors of the vasculature. Although circulatory anatomy may
indeed influence the dissemination of many malignant cells, it can not fully explain the patterns
of metastatic development since there is also evidence that tumor cell properties may determine
the outcome of malignancy (Hart et al., 1980).
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It is important to point out that Paget’s or Ewings hypotheses should not be defined as
mutually exclusive; rather they are both correct and overlaping to a certain extent.
Cancer metastasis is a process that consists of sequential and independent steps, and
studies have shown that neoplasms go through a series of changes from the original benign
tumor into a lethal malignant disease state. For instance, tumors can originally be benign and
then transform into a malignancy. This has been attributed to the fact that these cells have
generated genetic variants in order to proceed through the metastatic cascade. These genetic
variations lead to tumor transformation and proliferation. Together with proliferation comes the
need for development of blood vessels and extensive vascularization (named angiogenesis) in
order to maintain tumor viability (Folkman, 1986). Next, the malignant cells detach from the
primary tumor and intravasate into blood vascular and lymph systems where they adhere to and
arrest in the vasculature of distant target organs. These malignancies then extravasate through the
blood vessel walls where they establish a tumor-host microenvironment which ultimately leads
to cell proliferation and metastasis formation (Fidler et al., 2002).
Although the mechanisms for metastasis are not well understood, it is known that
proteolytic enzymes play a role in the degradation of the ECM, which is essential for intra- and
extravasation of tumor cells and the formation of metastasis to distant organs (Liotta, 1986).
Therefore, a review of the role that proteolytic enzymes (specifically heparanase) and co-factors
play in cancer metastasis development is important.
2.2 Brain-Metastatic Melanoma
Malignant melanoma also represents one of the best characterized solid tumors with
respect to tumor invasion and metastatic spread (Hofmann et al., 2005). Usually the fatal step in
the progression of many malignant cancers is often tumors metastasizing to the brain. The
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frequency of melanoma occurrence and the morbidity of brain metastasis alone would be
sufficient reason for alarm, but when one combines these two factors, they make the area of
brain-metastatic melanoma a particularly important biological and clinical problem (Nicolson et
al., 1996).
The brain provides a unique target for malignant melanoma by being confined to the
skull. These brain metastatic tumor cells must penetrate a formidable blood brain barrier in order
to invade the brain tissue. Malignant melanomas metastasize to the brain with one of the highest
frequencies of any cancers that colonize the central nervous system (CNS) (Marchetti et al.,
2003a). Metastases to other parts of the body are generally tolerated and asymptomatic, but due
to the confined nature of the brain, tumor formation usually results in rapid decline in health
(Menter et al., 1994). This morbidity is usually due to cerebral edema which is a major
complication of CNS tumors. This build up of fluid on the brain is caused by the brain’s lack of a
lymphatic drainage system, and this creates problems for a closed environment where
homeostasis is important for normal brain function. These characteristics of the brain
microenvironment make treatment both difficult and necessary (Sawaya et al., 1996; Soffietti et
al., 2002).
2.3 The Role of the Extracellular Matrix in Cancer
It was originally thought that the extracellular matrix (ECM) surrounding tumor cells was
an inert scaffold only providing for cell growth and differentiation. It is now apparent that the
ECM plays essential roles in both normal and pathogenic cellular function and phenotype (Liu et
al., 2002a). The current direction of thought is that the ECM is an active participant in cell
signaling processes. This concept is based on the fact that ECM synthesis is highly regulated by
the cell, which uses the ECM to modulate and process signals at the cell surface thereby
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influencing cell function (Sasisekharan et al., 2000). The ECM is made of three major
components: the first component is the structural proteins which help maintain morphology by
providing tensile strength; the second component is proteoglycans which are protein core from
which heparan sulfate glycosaminoglycan extensions protrude; and the last component is soluble
signaling molecules like growth factor, cytokines, and chemokines that are bound to the ECM by
the heparan sulfate glycosaminoglycan chains (HSGAGs) (Lin et al., 2000).
An important area of trying to determine the mechanism of cancer metastasis and
development is the proteoglycan component of the ECM. There is much interest in proteoglycans
because they are present both in the ECM and at the cell surface, thus they are directly involved
in the cell-tissue interface. Proteoglycans are involved in both how the cell processes signals that
arise from the ECM, and also, how a signaling molecule that is released from the cell diffuses to
and is processed at a distant site (Liu et al., 2002a).
2.4 The Function and Structure of Proteoglycans
Proteoglycans are a superfamily of molecules that are distinguished by the covalent
attachment of one or more glycosaminoglycan chains (GAG) to a polypeptide core. Differences
in GAG composition are used to discern the four classes of GAGs that attach to core proteins:
chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS)/heparin, and keratin sulfate
(KS). The proteoglycans of interest are usually heparan sulfate proteoglycans (HSPGs) this is
because cell suface proteoglycans primarily have HS attached to them. Virtually all cells express
HSPGs at their cell surface, and a large number of genetic mutants that disrupt HS synthesis and
modification demonstrate that HS has a critical role in controlling how cells interact with
extracellular ligands (Kramer et al., 2003).
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Two families of polypeptides appear to carry the majority of the cell surface heparan
sulfate on mammalian cells: glypicans, which are attached to the plasma membrane via
glycosylphosphatidylinositol (GPI) anchors, and syndecans, which are transmembrane proteins.
Four syndecans and five glypicans, all encoded by separate genes, have been described to date
(Bernfield et al., 1992). HSPG expression is developmentally regulated and altered in various
pathological processes, including cancer. The expression patterns are believed to mirror those of
ligands that require HSPGs to elicit their cellular responses. For instance, syndecan-1 cell surface
expression is usually down-regulated in metastatic phenotypes. At the same time, syndecans are
shed from the cell surface as soluble molecules that regulate protease and growth factor activity,
and this soluble syndecan expression in tumors has been correlated with increased cancer
progression and invasion (Sanderson, 2001).
2.5 The Structure and Variability of Heparan Sulfate Glycosaminoglycans (HSGAGs)
HSGAGs are ubiquitously expressed on the surface of every eukaryotic cell and have
shown importance in the regulation of normal and pathological physiology (Sasisekharan et al.,
2002). HSGAGs are synthesized in the Golgi apparatus beginning with four monosaccharides
linking to the proteoglycan core protein, usually either a syndecan or a glypican. This chain is
then turned into a polysaccharide by the sequential addition a glucosamine linked to either
iduronic or glucuronic, and there are many possible disaccharide unit combinations for HSGAGs
(Gallagher, 2001). These different possibilities are based on the fact that O-sulfation can occur at
the 2-O position of uronic acid and at the 6-O and 3-O positions of the glucosamine. This creates
eight different combinations because each site can be either sulfate or unsubstituted. There is
also the opportunity for sixteen additional different combinations of disaccharides by the fact
that there are two possibilities for the uronic acid component which can be either iduronic acid or
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glucuronic acid. Lastly, the N-position of the glucosamine has three possible states in that it can
be either sulfated, acetylated, or unsubstituted, which results in 48 different possibilities for
disaccharide building blocks. This gives HSGAGs over 30 times as many possible variations as
that of polypeptides and 10,000 times that of DNA, having the potential for a staggering degree
of variation (Esko et al., 2001).
The result of HSGAGs having such a vast structural diversity is that they have the ability
to bind and interact with a various array of proteins which includes growth factors, chemokines,
morphogens, and enzymes. Growth factors, such as insulin like growth factor, basic fibroblast
growth factor (bFGF), platelet-derived growth factor (PDGF), and vascular endothelial growth
factor (VEGF), have shown to have important roles in the process of tumor development (Iozzo,
2001; Marchetti et al., 2003b; Nurcombe et al., 2000; Sasaki et al., 2004). The specificity of
these interactions is dependent on HSGAG sequence, spacing of binding sites, and the threedimensional structure of the HSGAG chain. These various HSGAG functions are important for
both signaling molecules and enzymes to function in an appropriate manner.
2.6 HSGAGs in Cancer Development and Metastasis
HSGAGs have been shown to be involved in the transformation of a normal target cell to
a cancer cell. It has been demonstrated that HSGAGs present on tumor cells contain bioactive
sequences that effect several aspects of tumor-cell phenotype in relation to cell growth and
metastasis. Tumor cell surface HSGAGs can promote growth factor signaling and tumor cell
proliferation (Sasisekharan et al., 2002). The fibroblast growth factor receptor (FGF) family,
which has diverse roles in regulating cell proliferation, migration, and differentiation when
inappropriately expressed, can contribute to the pathogenesis of cancer. There are numerous
levels of evidence implicating the differential ability of HSGAGs in regulating FGF signaling via
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their cell surface tyrosine kinase receptors (FGFR). For example, it has been observed that the
specificity of a given FGF to a FGFR is mediated by what appears to be distinct tissue-specific
HSGAG sequences, and tumor cells have been reported to control the affinity that HSPGs and
growth factors like basic fibroblast growth factor (bFGF) have for each other by altering the
density and sulfation patterns of their HSPGs (Sasisekharan et al., 1994). The expression of and
the structural integrity of HSGAGs on the cell surface have shown to change with the metastatic
transformation of certain cell types (Kure et al., 1987). For example, it has been shown that B16
melanoma cells with high metastatic propensities have a lower concentration of cell surface
HSGAGs than sublines with less metastatic potential. It has also been shown that highly
metastatic B16 sublines degrade HSGAGs faster than sublines of lower metastatic spread
(Nakajima et al., 1983)
HSGAGs are not randomly involved in cancer metastasis, rather they play intricate roles
in this multi-step process. In order for a tumor to develop beyond a diameter size of 1-2 mm, an
increase in vascularity is necessary, and HSGAGs are directly involved with the angiogenic
process (Iozzo, 2001). In fact, bFGF has a dual role in its interaction with HSGAGs in that it is
involved with tumor growth, and it is also involved with the development of new blood vessels.
HSGAGs which are present on endothelial cells can indirectly effect tumor growth; they can
either enhance or inhibit neovascularization by regulating signal transduction of bFGF or
vascular endothelial growth factor (VEGF). In addition, HSGAGs have dual roles in tumor
metastasis as well. Since HSGAGs are at the interface between tumor cells and normal host cells,
it allows for them to mediate tumor and host cell interactions (Raman et al., 2003). HSGAGs
regulate tumor metastasis to sites such as the brain by arbitrating interactions between cancer
cells and platelets and endothelial cells and host organ cells (Varki et al., 2002). HSGAGs are
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also involved in attempts to deter metastasis by acting like barriers in the ECM. This HSGAG
barrier, however, is overcome by invading tumor cells that secrete degradative enzymes. Studies
have shown a direct correlation between the production of heparanase, an enzyme that degrades
the polysaccharide component of the ECM, and the invasiveness of tumor cells (Vlodavsky et
al., 2001).
2.7 The Function of Heparanase in Tumor Progression and Metastasis
Heparanase (HPSE-1) is an enzyme that was first identified in the B16 murine metastatic
melanoma cell sublines (Hook et al., 1975). It was shown in these B16 sublines that HPSE-1
correlated with lung metastasis potential (Nakajima et al., 1983). Since that time, HPSE-1 has
been linked to a wide number of cancers including bladder, colon, gastric, breast, pancreatic, and
brain (Friedmann et al., 2000; Gohji et al., 2001; Koliopanos et al., 2001; Marchetti et al., 2001;
Maxhimer et al., 2002; Tang et al., 2002). This suggests that HPSE-1 plays a role in the sustained
development and pathology of malignant diseases and would make a good potential target for
cancer therapy (McKenzie et al., 2003).
Heparanase is an endo-β-D-glucuronidase that affects various biological processes
through degradation of the ECM and release of HS-bound growth factors, cytokines, and
enzymes. Heparanase participates in ECM desolation by invading cells, and HPSE-1 enzyme
activity has been detected in several types of normal hematopoietic cells, including neutrophils,
megakaryocytes, and activated lymphocytes and may mediate their extravasation during
inflammatory and immune responses (Matzner et al., 1992; Nakajima et al., 1988; Schubert et
al., 2004). Additionally, heparanase has been identified as a participant of embryogenesis (Revel
et al., 2005), but is mainly known for its role in cancer invasion and metastasis. HPSE-1 does
more than simply degrade and remodel extracellular matrix. HPSE-1, rather than fully digesting
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HSGAGs, cleaves HSGAGs at only a few sites, producing fragments that are 10–20 sugar
residues long. There is also evidence that the fragments of heparan sulfate generated by
heparanase are more biologically active than the native HSGAGs from which they are derived
(Sanderson et al., 2004). The human HPSE-1 gene is located on chromosome 4 and encodes a
543-amino-acid protein that has recently been purified and cloned (Hulett et al., 1999; Kussie et
al., 1999; Toyoshima et al., 1999; Vlodavsky et al., 1999). This protein was originally
synthesized as a 65 kDa glycosylated pro-enzyme that is activated by proteolytic cleavage to
remove a linker region and form an active heterodimer of 8 and 50 kDa polypeptides (Fairbanks
et al., 1999). The hydrolase activity of HPSE-1 works by cleaving the linkage between the
glucuronic acid and N-acetylglucosamine of the HSGAGs (Nakajima et al., 1983). The HPSE-1
enzyme activity is closely regulated by pH, achieving maximal activity under acidic conditions at
an optimum range between a pH of 5.5-8.8. This characteristic of HPSE-1 activity correlates
well with the notion that the microenvironment in tumors is generally more acidic than in normal
tissues. This acidity of the tumor microenvironment is found within hypoxic areas of growing
tumors (Tannock et al., 1989). Upon activation in this acidic environment, HPSE-1 facilitates the
release of several protein modulators that effect cell functions such as migration, adhesion,
inflammation, and angiogenesis. HPSE-1 activation then facilitates processes which are all steps
in the development of metastatic invasion (Hulett et al., 1999; Kussie et al., 1999; Nakajima et
al., 1988; Parish et al., 1987; Toyoshima et al., 1999; Vlodavsky et al., 1999; Vlodavsky et al.,
2001; Zetser et al., 2003).
2.8 Neurotrophins in Brain Metastasis and Heparanase Production
Metastasis is not a random event, and there are reasons that metastasis frequently occurs
in certain organs. The reasons for these metastatic patterns may lie within the stromal cells and
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the paracrine growth and differentiation factors that they secrete (Marchetti et al., 2004). The
first one of these factors to be purified and characterized was nerve growth factor (NGF). NGF is
important for the survival of and differentiation of neurons in both the sympathetic and central
nervous system (Marchetti et al., 1993). NGF is the prototype of a family of neurotrophins (NT)
which are a group of neurotrophic factors that are distinct from cytokines and FGFs. Although
NGF is the best characterized NT, it is also known that other family members like brain derived
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are also
involved as neurotrophic substances as well. The biological effects of NTs are mediated through
two unrelated classes of cell surface membrane receptors. All NTs can bind to p75 neurotrophin
receptor (p75NTR) which is a low-affinity receptor. There is, however, a family of high-affinity
Trk receptors that are bound selectively by certain NTs. For instance, NGF binds TrkA, BDNF
and NT4/5 bind TrkB, and NT-3 binds TrkC (Chao et al., 2002). When NT receptors (NTR) are
overexpressed in melanoma cells, they have shown to be more aggressive and have a stronger
survivability than cells that express low NTR levels (Marchetti et al., 2004). Binding of NGF
along with p75NTR being overexpressed has been characterized as giving cells both a survival
advantage and creating aggressive malignant melanoma cells. There are previous studies that
have shown that cells incubated with select NTs showed an increased ability to invade into a
membrane like matrix, but what was of greater interest is the fact that these NTs caused an
increase in HPSE-1 activity. The result is an NT-driven degradation of the ECM by HPSE-1
(Walch et al., 1999).
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CHAPTER 3: SELECTIVE HEPARANASE LOCALIZATION IN MALIGNANT
MELANOMA CANCERS
3.1 Introduction
Malignant melanoma has the unfortunate distinction of being the cancer type with the
highest increase in frequency of occurrence, especially among young adults. Mechanisms
responsible for melanoma’s progression to a highly aggressive metastatic disease are not fully
understood. However, it is known that proteolytic enzymes play important roles due to their
involvement in extracellular matrix (ECM) disassembly which allows melanoma cells to invade
distant organs (Bogenrieder et al., 2003). Heparanase (HPSE-1) plays a critical role in tumor
progression by degrading the heparan sulfate (HS) chains of HS proteoglycans (HSPG) and by
releasing angiogenic molecules stored within the ECM(Vlodavsky et al., 2001). HSPG are
present on the cell surface and in the ECM of tissues and their degradation has significant
regulatory consequences in cancer metastasis (Nardella et al., 2004). HPSE-1 is an enzyme that
was cloned in 1999 (Hulett et al., 1999; Kussie et al., 1999; Toyoshima et al., 1999; Vlodavsky
et al., 1999)as the first and thus far the only example of purification and cloning of a mammalian
HS degradative enzyme. HSPE-1 acts as an endo-β-D-glucuronidase cleaving HS glycosidic
bonds at specific intrachain sites resulting in the formation of fragments of appreciable size (1020 sugar units) (Nakajima et al., 1984; Nakajima et al., 1988; Vlodavsky et al., 2001). Its
hydrolase activity facilitates the release of several protein modulators that affect cell functions
such as migration, adhesion, inflammation, embryogenesis, angiogenesis, and metastatic
invasion (Hulett et al., 1999; Kussie et al., 1999; Marchetti et al., 1993; Marchetti et al., 1996;
Nakajima et al., 1988; Toyoshima et al., 1999; Vlodavsky et al., 1999; Vlodavsky et al., 2001).
Furthermore, elevated HPSE-1 mRNA levels correlate with reduced survival rates in post*Chapter 3 reprinted by permission of Professor D.A. Spandidos, the editor of International
Journal of Oncology.
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operative cancer patients (Vlodavsky et al., 1999; Vlodavsky et al., 2001). These observation led
us to hypothesize that HPSE-1 would be substantially elevated in melanoma tissues particularly
when compared to normal tissues from the same specimen. In the present report, we provide
first evidence that 1) HPSE-1 mRNA is significantly upregulated in lung metastatic melanoma
versus adjacent lung tissue; 2) HPSE-1 protein expression is significantly augmented in
metastatic melanoma clinical specimens while mostly negative in primary tumors; and 3) HPSE1 accumulates around blood vessels and vascular regions in brain-metastatic melanoma
specimens.
3.2 Materials and Methods
3.2.1 Tissue Culture and Experimental Metastasis Assays
Early-passage murine invasive melanoma cells (B16F1, B16F10 and B16B15b) were
maintained as monolayer cultures in a 1:1 (v/v) mixture of Dulbecco’s modified Eagle’s/ Ham’s
F-12 medium (DMEM/F-12) supplemented with 5% fetal bovine serum (FBS) (v/v). Cells were
maintained at 37°C in a humidified 5% CO2/95% air (v/v) atmosphere and were passaged using
2 mM Ethylene Diamine Tetra Acetic Acid (EDTA) in Phosphate buffered saline (PBS) before
reaching confluence, as previously reported (Marchetti et al., 1993; Marchetti et al., 1996).
Eight-week old female C57BL/6 mice were obtained from Harlan Sprague Dawley and
quarantined for 1 week. The mice were randomly divided into three groups with four mice in
each group receiving an injection of B16F1, B16F10, or B16B15b cells respectively. Injection
in the lateral tail vein (I.V.) was carried out using 2 x 106 cells suspended in serum-free medium
(200 µl). Mice were sacrificed after 17 days when they were moribund due to dyspnea.
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3.2.2 Surgical Specimens
Specimens were obtained from the Cooperative Human Tissue Network, Tissue
Procurement Facility, University of Alabama at Birmingham, AL, and from the Surgery
Department at the University Hospital of Udine, Italy. These specimens were obtained frozen
or were cut into 2x2x1 cm fragments, fixed in the 10% buffered formalin and paraffin
embedded. Sections (5 µm thick) were cut into sialinized slides. Following treatment, slides
were immunostained and examined in the Department of Pathobiological Sciences at the
Louisiana State University School of Veterinary Medicine to identify tumor samples that
contained metastatic melanoma as well as adjacent normal lung tissue. This resulted in the
selection of 10 cases of brain-metastatic melanoma with adjacent brain tissue, 25 cases with
metastatic melanoma to sites other than brain, and 10 cases of primary melanomas.
3.2.3 Tissue Preservation
Freshly dissected lungs were collected from mice, washed in cold diethylpyrocarbonate
(DEPC)-treated PBS, and then incubated at 4°C on a rocking platform for 24 hrs in 30% sucrose
(Parlato et al., 2002). The tissue was again rinsed with PBS and flash frozen in isopentone over
dry ice. Frozen sections were embedded in optimal cutting temperature medium (OCT) and
mounted on a cryomold.

Sections were subsequently cut (10 µm thick) at -25°C, fixed in

decreasing concentrations of ethanol (100 % EtOH, 70 % EtOH, and 50 % EtOH) for 20 sec
each, stained for 20 sec with cresyl violet acetate, and then again dipped in 50 % EtOH, 70 %
EtOH and in 100 % EtOH (two times). Slides were air-dried and stored at -80°C until used.
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3.2.4 Laser Cpture Mcrodissection Mcroscopy and RNA Extraction
Laser capture microdissection microscopy (LCMM) (Emmert-Buck et al., 1996; Fend et
al., 1999; Sugiyama et al., 2002) was performed using the P.A.L.M. Laser-MicroBeam System
(P.A.L.M., Wolfratshausen, Germany) following protocols provided by the manufacturer. The
P.A.L.M. system was used to dissect normal tissue from tumorigenic tissue for the differential
analysis of heparanase levels. Previously prepared slides were removed from -80°C just prior
to use to avoid potential RNA degeneration. The P.A.L.M. system catapulted tissue (104 to 1.5 x
104 cells) into the lid of a reaction tube covered with extraction buffer (0.5 ml; Arcturus Inc.,
Mountain View, CA).

The cap was inserted onto the reaction tube and the assembly was kept

on ice. Following an incubation step at 42°C for 30 min, total RNA was extracted following the
suggested protocol using the PicoPure RNA Isolation Kit (Arcturus Inc.). RNA was eluted
using the kit elution buffer (18 µl). Presence of RNA was confirmed by PCR with the
housekeeping gene GAPDH for murine samples and β-actin for human samples (Kreuzer et al.,
1999; Overbergh et al., 1999).
3.2.5 cDNA Synthesis and PCR Amplification
cDNA synthesis was performed with a reverse transcription (RT)-mixture (25 µl;
Promega, Madison, WI). First, RNA (13 µl) was incubated with 0.3 µg of oligo dTs
(Invitrogen, Grand Island, NY) at 70°C for 5 min. Then, 5 µl of 5x RT buffer, 0.5 mM dNTPs,
25 units of RNAsin, and 200 units of M-MLV (Promega) were added, and the final RT-mixture
was incubated at 42°C for 50 min with a heating step to 94°C for 2 min. PCR reactions were
performed with a PCR-mixture (25 µl) consisting of cDNA (2 µl), 2.5 µl of 10x PCR buffer, 0.2
mM dNTPs, 0.5 µM primers, and 1 unit of Taq Polymerase (Promega). PCR was first
performed with the housekeeping genes GAPDH (for murine samples) and β-actin (for human
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samples) to check for viable RNA. Samples testing positive for GAPDH or β-actin were tested
for the HPSE-1 presence. Amplification was performed using the GeneAmp PCR-system 9700
(Applied Biosystems, Foster City, CA). Human samples had an initial denaturation step at 94°C
for 5 min which was followed by 40 cycles of denaturation at 94°C for 30 sec and an
annealing/extension step at 67°C for 60 sec for human β-actin or 60°C for 60 sec for human
heparanase and murine GAPDH. The conditions for murine heparanase were 94°C for 5 min
followed by 35 cycles at 94°C for 30 sec, 60°C for 45 sec, and 72°C for 45 sec with a final
extension at 72°C for 10 min. Primer sequences and expected amplicon sizes are listed in Table
1. Agarose (1%) gel electrophoresis was subsequently performed.
3.2.6 Real-Time PCR
The fluorogenic probe used for real-time PCR analyses of murine heparanase contained
the reporter dye FAM covalently attached at the 5’-end and a quencher dye TAMRA at the 3’end (Applied Biosystems). The endogenous control used for murine samples in this study was
18S ribosomal RNA (Applied Biosystems), the reporter dye for 18S was VIC and the quencher
dye was TAMRA. All fluorogenic probes were HPLC-purified. Analysis was performed using
the ABI PRISM 7700 sequence detection system (Applied Biosystems). Amplification was
carried out in a reaction volume (30 µl) that consisted of cDNA solution (2.5 µl) from the RT
reaction, 2x TaqMan Mastermix (Applied Biosystems), 900 nM heparanase primer or 50 nM of
18S primer, and 200 nM of each probe in ddH2O. Amplification was performed in triplicate in
MicroAmp optical tubes using the standard amplification protocol as recommended by the
manufacturer.
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3.2.7 Quantification of HPSE-1 mRNA Expression
Using the internal fluorogenic oligonucleotide probes, each well was monitored for
fluorescent dyes, and signals were regarded as significant if the fluorescent intensity statistically
exceeded (10-fold) the standard deviation of baseline fluorescence as Threshold cycle (CT). CT
was defined as the cycle at which a significant increase in emission intensity was first detected.
Relative mRNA quantitation was performed using 18S as the housekeeping gene and the
comparative ∆∆CT-method as previously described (Brink et al., 2000).
3.2.8 Immunohistochemistry for Murine Samples
Immunohistochemical staining was performed using a Vectastain ABC kit (Vector
Laboratories, Inc., Burlingame, CA) according to the instructions provided by the manufacturer.
Formalin-fixed, paraffin-embedded tissue sections were mounted on silanized slides (Fisher
Scientific, Springfield, NJ) and deparaffinized. Endogenous peroxidase was blocked by
incubating the sections in H2O2 (3.0%). After the blocking of nonspecific reactivity with rabbit
serum for 30 min at room temperature (25°C), sections were incubated at 4°C for 60 min
using HPSE-1 rabbit polyclonal antibody raised against human HPSE-1 and crossreacting with
the murine enzyme (Pharmacia-Upjohn Inc., Kalamazoo, Michigan). Following rinsing, slides
were incubated with biotinylated anti-rabbit IgG and then with Vectastain ABC reagent.
Peroxidase activity was determined using the NovaRED substrate kit (Vector Laboratories Inc.),
and the slides were counterstained with Mayer’s hematoxylin. As a negative control, sections
were subjected to normal serum blocking with omission of the primary antibody.
3.2.9 Immunohistochemistry for Human Samples
Sections were prepared from human melanoma tissue samples which had been formalinfixed and paraffin-embedded. The tissues were sectioned at 5 µm, mounted on silanized slides,
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heated, deparaffinized, and rehydrated. Endogenous peroxidase was blocked with a H2O2
solution (3.0%). Slides were pretreated with proteinase K and then blocked with horse serum.
Sections were incubated at room temperature (25°C) for 30 min using a mouse monoclonal
antibody raised against human HPSE-1 (2 mg/ml, diluted 1:200 and 1:500) (Tsukuba Research
Institute, Novartis Pharma K.K., Takarazuka, Japan). Additionally, a mouse monoclonal
antibody directed against human endothelial marker CD34 was also used (Cell Marque, Hot
Springs, AR). Following rinsing, slides were incubated with biotinylated goat anti-mouse IgG
and then with Vectastain ABC reagent (Vector Laboratories). Peroxidase activity was
determined using the NovaRED substrate kit (Vector Laboratories), and slides were
counterstained with Mayer’s hematoxylin. Control sections were treated identically but an
isotyped matched mouse monoclonal antibody was used as the primary antibody.
3.2.10 Statistical Analysis
Staining of each section was assigned scores ranging from 0 to 4+ as follows: negative
(0), weakly positive (1+), moderately positive (2+), positive (3+), and highly positive staining
(4+). For IHC determinations, positive cases were those that stained with an intensity score of ≥
1, baseline mark for staining positivity.
All results comparing tumorigenic tissue versus normal tissue were analyzed using the paired
Student’s t-test. They were considered significant if p < 0.05.
3.3 Results
3.3.1 Melanoma Development in Mice
To examine for HPSE-1 presence, mice were inoculated with B16F1, B16F10, or B16B15b
melanoma cells and sacrificed 17 days later when they exhibited severe signs of dyspnea.
Necropsy was performed with primary emphasis on lung tissue, and necropsy showed severe
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infiltration of this tissue with black fragile nodules. Histological analyses confirmed the
pulmonary nodules to be melanoma metastasis. A representative experiment showing of lungmetastatic melanoma in a mouse injected with B16F10 cells is shown (Figure 3.1).
3.3.2 Localization of HPSE-1 in Metastatic Melanoma Lesions
In order to obtain the precise RNA content of melanoma tissue, we employed laser
capture microdissection microscopy (LCMM) to avoid contamination between cancerous and
normal tissue samples.

LCMM is beneficial because it allows for specific isolation of very

small tissue samples (Emmert-Buck et al., 1996; Fend et al., 1999; Parlato et al., 2002; Sugiyama
et al., 2002). Furthermore, LCMM makes real-time PCR (RT-PCR) and PCR analysis of very
small tissue samples more feasible and reproducible. Melanotic and normal pulmonary cells
could be efficiently isolated into different samples. Since the cancer metastasized to the lung, we
used similar populations of normal lung tissues as controls for HPSE-1 analysis. The process of
laser capture microdissection of melanoma tissue is shown in Figure 3.2.
In order to confirm that RNA extractions worked, PCR was performed on all samples as
shown (Table 3.1). In murine samples, PCR was performed using GAPDH as the housekeeping
gene. The GAPDH gene showed good RNA extractions in ten out of twelve samples, and
samples that tested negative were from the two mice that died before they could be euthanized.
Once the samples tested positive for the housekeeping gene, analysis for murine heparanase was
performed. The PCR for murine heparanase demonstrated the expected 205 bp band in the
tumor samples; however, all samples from adjacent normal tissue tested negative for HPSE-1
cDNA presence (Figure 3.3).
3.3.3 HPSE-1 mRNA is Upregulated in Murine Melanoma Tissues
Because HPSE-1 has been shown to be involved in cancer invasion, angiogenesis,
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Figure 3.1 A Representative Experiment of Lung-Metastatic Melanoma.
Murine malignant melanoma cells were injected intravenously (tail vain injection) in 6-week old
female mice (C57BL/6). At the end of experimental period, mice were euthanized, and the lungs
with metastatic melanoma were extracted and preserved for subsequent analysis.
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A

B
NLT

NLT

Melanoma

Figure 3.2 Detection and Extraction of Melanoma Cells in Lung Tissues by LCMM.
Sections before (A) and after (B) LCMM, showing the remaining cells on the slide. NLT,
normal lung tissue. Melanoma cells are indicated.
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Table 3.1 Sequences of PCR Primers and Sequence Specific Probes for Different
Targets.
Primer

Sequence (5’-3’)

Amplicon
Length
(bp)

GAPDH

forward
probec
reverse

TTCACCACCATGGAGAAGGC
TGCATCCTGCACCACCAACTGCTTAG
GGCATGGACTGTGGTCATGA

236

18Sa

probed

Supplied by Perkin Elhmer (4308310)

187

HPSE-1

forward
probec
reverse

GACAAGGAACCGACTTCCGAAGAA
Performed by Perkin Elhmer
CTGTAGAGCATGTCCACTGAGCTT

205

GAPDHb

probee

Supplied by Perkin Elhmer (402869)

226

β-actinb

forward
reverse

AGCCTCGCCTTTGCCGA
CTGGTGCCTGGGGCG

180

HPSE-1b

forward
probec
reverse

TCGTGGACCTGGACTTCTTCA
CCACGGACCCGCGGTTCCT
ACAAGCCTCTGGCCAAGGTA

150

Target
Sequence
a

a

a

c

Sequence for murine sample
b
Sequence for human sample

FAM-labeled DNA probe
VIC-labeled DNA probe
e
JOE-labeled DNA probe
d
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Figure 3.3 Agarose Gel Electrophoresis Showing PCR for Expression of Murine
heparanase in Metastatic Melanoma and Adjacent Lung Tissues Obtained by
LCMM.
(A) Lanes 1 to 8: melanoma tissue samples; Lane 9: negative control (H2O); Lane 10: positive
contol (B16F10). (B) Lanes 1 to 9: normal lung tissue samples; Lane 10: negative control
(H2O); Lane 11: positive control (B16F10).

and metastasis, we determined comparative and quantitative HPSE-1 mRNA levels in tumor
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versus normal tissues. We performed real-time PCR to determine whether heparanase is
upregulated in metastatic tissue versus normal tissues.

The first choice as a murine

housekeeping gene for sample normalization was murine GAPDH. With GAPDH as the
housekeeping gene there was a marked difference in CT values between normal tissue and tumor
tissue throughout all samples. This difference was up to 16 CT values difference between
samples, which corresponds to a 216 or 65,536-fold difference. For this reason, GAPDH could
not be used for the housekeeping gene. Analysis of ribosomal 18S expression as a different
housekeeping gene showed a similar result, but the trend was not nearly as profound. Data of
quantitative expression analysis for HPSE- 1 was normalized to the housekeeping gene 18S
(Table 3.2). The melanoma samples after normalization had an average ∆CT value of 10, and
the average ∆CT value for normal lung was 14.86 (Table 3.2). The average calculated ∆∆CT
value (normal minus melanoma) was 4.86, which corresponds to a 29-fold increase of
heparanase mRNA expression in melanoma tissue (Figure 3.4). Results for ∆∆CT were shown to
be significant to p < 0.05. CT values for individual sample ∆CT’s are indicated in Table 3.2.
3.3.4 Elevated HPSE-1 Expression in Metastatic Melanoma Lesions
Immunohistochemistry was performed for the presence of heparanase with anti-HPSE-1PAb on paraffin-embedded, lung-metastatic samples from mice.

We observed an intense

immunostaining for heparanase detected on the cell-surface and ECM for each of melanoma
tumors samples. A representative experiment HPSE-1 immunostaining is shown in Figure 3.5.
Immunostaining for HPSE-1 also tested positive in all human samples of metastatic melanoma.
Conversely, primary melanoma tumors were mostly negative for HPSE-1. In metastatic
melanoma to brain, 8 cases had very intense staining for HPSE-1 (Figure 3.6). Of note, HPSE-1
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Table 3.2 Comparison of HPSE-1 mRNA in Adjacent Normal and Metastatic Melanoma
Tissues Melanoma by Quantitative Real-Time PCR.
∆ CT

∆ CT

∆∆ CT

melanoma tissue

normal tissue

Mouse 1

6.8a

14.0

7.2

Mouse 2

N.D.b

15.0

N.D.

Average

Mouse 3

9.1

13.9

4.8

∆∆ CT = 4.91

Mouse 4

9.9

15.7

5.8

Mouse 5

15.5

16.0

0.5

Mouse 6

N.D.

17.3

N.D.

Average fold

Mouse 7

9.5

10.1

0.6

difference

Mouse 8

10.0

14.0

4.0

F = 24.9 = 29.1

Mouse 9

9.8

N.D.

N.D.

Mouse 10

9.6

17.8

8.2

Average

10.0c

14.9c

Std.dev.

2.44

2.29

a

Samples were normalized against the housekeeping gene 18S.

b

N.D. = not detectable.

c

Statistically significant at p < 0.05.
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Figure 3.4 HPSE-1 Quantification in Normal Versus Melanoma Tissues. Quantitation
levels were detected by TaqmanTM RT-PCR followed by ∆∆CT analysis. Mice were injected with
murine melanoma cells (B16F1, B16F10, or B16B15b). Once the mice showed signs of
dyspnea, they were sacrificed, and total RNA was isolated from normal (9 samples) and
tumorigenic (8 samples) lung tissue. Optimized reverse transcription of RNA and amplification
of specific cDNA were performed using the ABI Prism 7700 Sequence detection system
(Applied Biosystems; see also “Materials and Methods”). Significant PCR fluorescent signals
(CT) for heparanase were normalized to an endogenous reference (18S). RT-PCR was performed
in triplicates. Data were considered significant if p < 0.05.
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Figure 3.5 HPSE-1 Immunostaining in Murine Metastatic Melanoma.
Mice (C57 BL/6) were injected with melanoma cells and subsequently lung-metastatic
melanomas were extracted and formalin fixed for immunohistochemistry. Intense peroxidase
staining of HPSE-1 was observed using anti-HPSE-1 PAb (see also ”Materials and Methods”).
(A) Hematoxylin and eosin staining. (B) Anti-HPSE-1 PAb staining. (C) Nuclei stained by
hematoxylin as a negative control. Digital images were produced on an Axioplan microscope
with Advanced Spot imaging program (Diagnostic Instruments Inc., Sterling Heights, MI) with
20x objective using identical conditions for all photographs.
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Figure 3.6 HPSE-1 Expression in Human Melanoma Tissues.
HPSE-1 immunohistochemical analyses of clinical specimens were performed as described in
Materials and Methods using the anti-human HPSE-1 monoclonal antibody. Primary tumor (AC) staining was negative for HPSE-1 (B) while immunostaining of lymph node tumor tissue (DF) showed moderate positivity for heparanase (E). However, brain-metastatic melanoma tissue
(G-I) showed intense staining for heparanase (H). Digital images were produced on an Axioplan
microscope with Advanced Spot imaging program (Diagnostic Instruments Inc., Sterling
Heights, MI) with 20x objective using identical conditions for all photographs. Hematoxylin and
eosin slide (A, D, G), Anti-HPSE-1-MAb staining (B, E, H), and nuclei stained by hematoxylin
as a negative control (C, F, I).
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was found to aggregate around blood vessels in four out of eight brain metastatic melanoma
samples (Figure 3.7), which was not unexpected due to the role that heparanase plays in
angiogenesis. Vascularity was confirmed by staining with CD34 antibody (Kelly et al., 2003).
3.4 Discussion
In this study, we examined the relationship between the in vivo expression and
localization of the ECM degradative enzyme heparanase (HPSE-1) and metastatic melanoma.
We provide, for the first time, evidence that 1) HPSE-1 is detected in in vivo cases of malignant
melanoma, 2) a correlation exists between metastatic melanoma cancers and HPSE-1 expression,
and 3) elevated HPSE-1 levels are found around microvessels in melanoma specimens.
Heparanase has been shown to correlate with the metastatic potential of a variety of
tumor-derived cell lines and tissue specimens, attributable to the enzyme involvement in ECM
remodeling (Nakajima et al., 1986; Vlodavsky et al., 2001). This list includes rat mammary
adenocarcinoma, murine fibrosarcoma, human colon carcinoma and murine/human melanoma
cell lines (Toyoshima et al., 1999; Vlodavsky et al., 2001; Zetser et al., 2003). Low-metastatic
murine T-lymphoma and melanoma cells transfected with the heparanase cDNA acquire a highly
metastatic phenotype in vivo (Wang et al., 1997). Thirdly, HPSE-1 is known to stimulate
vascular endothelial cell invasion and to induce angiogenesis in several types of cancer
(Vlodavsky et al., 2001).
Our results showed that HPSE-1 expression and localization in metastatic melanoma
cases is significantly higher than in corresponding tissues surrounding melanoma metastases or
in non-invasive, non-metastatic primary melanoma specimens. We also demonstrated its these
findings indicate that heparanase may have a central role in promoting both cell expression and
localization around blood vessels in melanoma clinical specimens. Overall, invasion and
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Figure 3.7 Elevated HPSE-1 Expression Around Blood Vessels in Metastatic Melanoma.
(A) Nuclei stained by hematoxylin as a negative control. (B) Hematoxylin staining with antiHPSE-1 PAb showing increased HPSE-1 expression in regions around blood vessels in 4 of 8
brain metastatic melanoma samples. (C) Identification of vessels by endothelial staining with
antibody to CD34. Digital images were produced on an Axioplan microscope with Advanced
Spot imaging program (Diagnostic Instruments Inc., Sterling Heights, MI) with 20x objective
using identical conditions for all photographs.
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angiogenesis are needed for the sustained growth of malignant melanoma.
Many important endogenous angiogenic factors such as basic fibroblast growth factor
(bFGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and
others have been reported in malignant melanoma at significantly higher levels at invasive stages
of the disease during its progression to the metastatic phenotype (Bogenrieder et al., 2003). For
example, VEGF overexpression can enhance growth of melanoma in the brain (Oku et al., 1998),
being necessary but not sufficient for brain-metastatic growth (Yano et al., 2000). Moreover,
bFGF levels in patients with metastatic melanoma are also significantly higher than those in
patients with non-invasive primary melanoma (Birck et al., 1999). Finally, these factors are
overexpressed in multiple malignant melanoma cell lines and in the serum of malignant
melanoma patients (Ugurel et al., 2001) with most melanoma cells expressing HSPG that can act
to concentrate these growth factors on their cell surface (Reiland et al., 2004). Accordingly, two
considerations can be made. First, cleavage of HS within ECM and particularly within the
basement membrane may be required for the migration of metastasizing melanoma cells and for
remodeling of the vasculature during angiogenesis. Second, HPSE-1 can directly promote
angiogenesis by releasing heparin-binding angiogenic growth factors such as bFGF and VEGF
that are trapped within the ECM and/or present on the cell surface. This idea is supported by the
finding that HPSE-1 increases the angiogenic response to tumors and that enhanced HPSE-1
mRNA expression correlates with tumor vascularity (Vlodavsky et al., 1999).
The mechanisms by which heparanase facilitates cancer progression likely involves more
than just remodeling ECM or releasing growth factors. There is evidence that the fragments of
heparan sulfate released on HS degradation maintain bioactivity and may, in fact, be more active
than the native HS chains from which they are derived. In a landmark study, it was discovered
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that HS fragment can either promote or inhibit the growth and metastasis of these melanoma
tumors (Liu et al., 2002b).

Thus, encoded within intact HS chains are cryptic structural

elements that have the power to either positively or negatively impact the behavior of cancer
cells. HPSE-1 can be relevant because its enzymatic action produces these cryptic fragments
with resulting biological consequences. It will therefore be critical to determine the specific
function of HS fragments generated by HPSE-1 degradation in melanoma cells, and how these
fragments modulate tumor cell behavior.
As a further level of complexity, it is known that a balance between ECM degradative
enzymes and their natural inhibitors controls the overall activity of these enzymes in invasion
and metastasis. For example, demonstration that ratios of ECM-degrading matrix
metalloproteinases (MMPs) to tissue inhibitors of MMPs are important in cancer invasion and
metastasis have been reported (DeClerck et al., 1992). It is likely that HPSE-1 is also regulated
by endogenous inhibitors in normal and tumor tissues. Recently, eosinophil major basic protein
has been reported as the first identified natural heparanase-inhibiting protein (Temkin et al.,
2004). Possibly other natural HPSE-1 inhibitors can be present in melanoma cells (Keren et al.,
1989).
In conclusion, our results indicate that HPSE-1 is expressed during metastasis and
angiogenesis of melanoma cancers. Thus, HPSE-1 can be a new target molecule to inhibit
invasion, angiogenesis, and metastasis of this disease and a new prognostic factor of patients
with malignant melanoma.
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CHAPTER 4: DEVELOPMENT AND USE OF A BRAIN SLICE MODEL TO STUDY
MECHANISMS OF CANCER METASTASIS TO THE BRAIN
4.1 Introduction
Brain-metastatic melanoma and elevated levels of heparanase (HPSE-1) are known to be
strongly correlated. Elevated levels of HPSE-1 have been shown to correlate with increased
aggressiveness of metastatic tumors. It is known that patients with metastic disease show
elevated levels of HPSE-1 in their sera and urine (Kelly et al., 2003; Nakajima et al., 1988), and
post-operative patients with high HPSE-1 mRNA levels have a reduced chance of survival
(Vlodavsky et al., 1999; Vlodavsky et al., 2001).
Malignant cells respond to paracrine and autocrine growth factor that are differentially
expressed in several organs and tissues. These differential patterns of growth factor expression
are a great determinant in the organ preference for metastatic colonization and growth. The
primary and most well characterized paracrine factor is nerve growth factor (NGF) (Marchetti et
al., 1990; Marchetti et al., 1993). NGF and NGF receptor expression are highly upregulated in
melanoma progression to the highly aggressive brain metastatic-phenotype. NGF is also
associated with enhancing heparanase production in brain metastatic melanoma (Marchetti et al.,
2004; Walch et al., 1999).
The orthotopic brain slice model is a method where by cultures of nervous tissue can be
maintained at the interface between the air and culture medium (Matsumura et al., 2000; Ohnishi
et al., 1998; Stoppini et al., 1991). These cultures maintain brain cytoarchitecture such as cortical
lamination and pyramidal cells. In addition, these tissues cultures retain the biochemical and
electrophysiological properties of neural cells for up to one month in culture. This model makes
it possible to investigate molecular events outside of the living body, which normally only occur
in vivo (Matsumura et al., 2000; Ohnishi et al., 1998). The purpose our study was to use this
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method to investigate the effects that both HPSE-1 and NGF have on brain metastatic melanoma
cells and their invasive properties while being able to monitor the cells in in vivo-like conditions.
Importantly, this brain slice model allows the ability to monitor tumor invasion at both
quantitative and qualitative levels. In fact, brain-metastatic melanoma cells showed a
significantly different invasion pattern depending on whether they where pre-treated with HPSE1 or with NGF. Additionally, melanoma cells plated on these organotypic cultures showed a
differential HPSE-1 expression at the protein level during time course experiments.
4.2 Materials and Methods
4.2.1 Cell Lines and Their Transfections and Cell Culture Conditions
The murine brain-metastatic cell line B16B15b was grown as a monolayer culture
(Marchetti, 1993, Marchetti, 1996). Early-passage cells were stably transfected with enhanced
green flurescent protein (EGPF) DNA using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA).
B16B15b cells were transfected in a T25 flask, and for each tranfection 5µg of EGFP DNA and
12 µl of LipofectAMINE 2000 were incubated for 5 minutes. Following incubation, 250 µl of
Opti-MEM (Invitrogen) was added and incubated for an additional 20 minutes. The EGFP,
LipofectAMINE 2000, Opti-MEM solution was added to cells in addition to fresh Ham’s F-12
medium supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) (v/v) and
blasticidin (10µg/ml) (Invitrogen) (1 ml). The flask was then placed in the incubator and the
medium was changed within 6-24 hours. B16B15b-GFP cells were maintained as monolayer
cultures in a 1:1 (v/v) mixture of Ham’s F-12 medium supplemented with 10% fetal bovine
serum (FBS) (Hyclone) (v/v) and blasticidin (10 µg/ml). Cells were maintained at 37°C in a
humidified 5% CO2/95% air (v/v) atmosphere and passaged using EDTA (2 mM in PBS) before
reaching confluence.
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4.2.2 Brain Slice Model Detecting Malignant Melanoma Cell Invasion
The brain tissue used for the organotypic brain slice models were obtained from 6-8 week
old female C57BL/6 mice that were attained from Harlan Sprague Dawley (Indianapolis, IN).
Prior to euthanasia they were quarantined for 1 week, and then housed in a barrier facility and
fed Purine Lab Chow 5001. Mice were first anaesthetized with isoflurane and killed by
decapitation. The mouse head was then plunged into 1% povidone-iodine solution. The brain
was subsequently extracted from the skull and immediately submerged in ice cold sterile PBS.
Next, the anterior portion of the brain was mounted and imbedded in a 3% agarose column with
the anterior portion of the brain facing upward. Finally, coronal sections of the brain that were
500 µm thick were obtained with a vibratome. The brain sections were then transferred onto the
polycarbonate membrane with a (0.4 µm) pore size in the upper chamber of a transwell tissue
insert in a six well plate (Corning, Corning, New York), and 2 ml of DMEM/F12 medium
supplemented with 10% FBS, and 100 units/ml of penicillin and streptomycin were added to the
bottom well of the six well plate. After allowing the brain to equilibrate for 24 hours, B16B15bGFP cell suspension (1x105 cells) was plated on the surface of the caudate nucleus and incubated
for different amounts of time.
4.2.3 Brain Slice Neuronal Viability Assays
Neuronal viability in brain slices was assessed in terms of cellular uptake of propidium
iodide (PI) (Sigma, St. Louis, MO) before and after the treatment with N-methyl-D-aspartic acid

(NMDA) (Sigma). Morphological examinations were performed periodically on sections that had
been incubated for longer than 72 hours. Brain slices were incubated with PI, after a 15 min
exposure to 100 µM NMDA, for 1 hour or 24 hours. PI signals were viewed with a TRITC filter
under a fluorescence microscope. PI was dissolved in a serum-free solution containing 75%
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MEM, 25% phosphate buffered saline (PBS), 2 mM L-glutamine and 6.5 mg/ml glucose to a final
concentration of 4.6 µg/ml as previously reported (Matsumura et al., 2000; Ohnishi et al., 1998).
4.2.4 Brain Slice Model Invasion Assay with Heparanase and NGF-treated Cells
Invasive properties of melanoma cells were assayed by using an orthotopic brain slice
model. For invasion assays, B16B15b-GFP cells were suspended in DMEM/F12 medium
supplemented with 10%FBS, and 100 units/ml of penicillin and streptomycin at a concentration
of 2x105 cells/µl. Directly before implanting melanoma cells on the brain slices either NGF or
HPSE-1 was added to the cell suspension at a final concentration of 862 µM. Next, cells (1x105
in 0.5 µl ) were implanted superficially on the caudate putamen of each brain slice, three brain
slice treatment groups per six well plate, and incubated for 72 hours. As a negative control, B16
B15b-GFP cells were suspended in the same medium previously mentioned and implanted on the
brain slice without any treatment.
4.2.5 Brain Slice Model Time Course Assay
HPSE-1 expression patterns of malignant melanomas were monitored at different points
of invasion through a time course assay. B16B15b-GFP cells were suspended in medium and
plated as previously mentioned. Melanoma cells were implanted without any additional
treatment and cells were incubated for 2, 12, and 24 hours respectively.
4.2.6 Tissue Preservation
After B16B15b-GFP cells and the brain slice were allowed to incubate, tissue sections
were rinsed in sterile PBS and then fixed in formalin for 24 hours. Following formalin fixation,
the brain slices were rinsed in sterile PBS and then incubated for 24 hours in 30% sucrose in PBS
(Parlato et al., 2002). The tissue was rinsed with PBS again and flash frozen in isopentone over
dry ice. The frozen sections were embedded in (Optimal Cutting Temperature medium) OCT and
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mounted on a cryomold, and 10 µm thick serial sections were taken from a superior view of the
500 µm brain slices cut at -28°C (Emmert-Buck et al., 1996; Sugiyama et al., 2002).
4.2.7 Immunohistochemistry
Immunohistochemical staining was performed using a Vectastain ABC kit (Vector
Laboratories, Inc., Burlingame, CA) according to the instructions provided by the manufacturer.
Briefly, formalin-fixed, OCT embedded tissue sections were mounted on poly-D-lysine coated
silanized slides. Endogenous peroxidase was blocked by incubating the sections in 3.0% H2O2.
After the blocking of nonspecific reactivity with rabbit serum for 30 min at room temperature
(25°C), sections were incubated at 4°C for 60 min with the anti-rabbit polyclonal GFP anti-body
raised against all variants of recombinant Aequorea GFP (Novus Biological Inc., Littleton, CO),
or with anti-human HPSE-1 rabbit polyclonal anti-body raised against human heparanase
(Pharmacia-Upjohn Inc., Kalamazoo, MI).

Following rinsing, slides were incubated with

biotinylated anti-rabbit IgG and then with Vectastain ABC reagent. Peroxidase activity was
determined using NovaRED substrate kit (Vector), and the slides were counterstained with
Mayer’s hematoxylin. As a negative control, sections were subjected to normal serum blocking
with omission of the primary antibody.
4.2.8 Brain Slice Model Invasion Assays
Serial sections were taken from brain slices that had been implanted with treated
melanoma cells or corresponding non-treated control cells. Immunohistochemistry was
performed on these serial sections with anti-GFP PAb in order to definitively mark the
B16B15b-GFP cells that had invaded into the brain slice tissue. Analysis of serial sections was
performed blindly with a representative tissue sample. Invasion was measured in two different
ways. First, invasion of melanoma cells was defined as the number of cells invading beyond the
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surface of the brain per unit of area. The second method used to determine invasion was defined
by measuring the depth of the most invasive cells per brain slice. The same counting area was
used for each sample measurement followed by statistical analysis.
4.2.9 Statistical Analyses
All statistical analyses were conducted with the SAS® statistical package (version 9.1.2).
To determine if there was a correlation between the number of cells invading and the depth of
cell invasion, the Pearson correlation coefficient was calculated and significance was tested. In
order to establish if this correlation could be used as a predictive model for overall cell
invasiveness, regression analysis by treatment group was performed. Analysis of covariance was
performed looking at heterogeneity of the slopes with cells as a covariate in order to conclude if
there was a difference in invasion between treatment groups. All tests were considered
significant at P < 0.05.
4.3 Results
4.3.1 HPSE-1 Increases the Number of Invading Cells Using a Brain Slice Model
In order to determine the effect of HPSE-1 on brain tumor invasion, B16B15b-GFP cells
were treated with HPSE-1 and implanted onto an orthotopic brain slice and incubated for 72
hours. Immunohistochemistry was performed looking to visualize GFP with anti-GFP
polyclonal antibody on OCT-embedded brain slice sections. Because the B16B15b-GFP
melanoma cells were stably transfected, staining for GFP was a decisive way to mark invading
cells with the results shown in Figure 4.1. Upon analysis of serial brain sections, HPSE-1
showed a two fold increase in the number of cells counted when compared to corresponding
control groups (Figure 4.2). However, when analyzing HPSE-1 invasion as a function of cell
depth into the brain tissue there was a relatively small difference between HPSE-1 treated cells
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Figure 4.1 The Brain Slice Model Invasion Assay
Representative picture of invasion of tumor cells by using a brain slice model. Murine malignant
melanoma cells stably transfected with green fluorescent protein B16B15b-GFP cells were
plated on the caudate putamen of an organotypic brain slice as part of an invasion assay. After
incubating (72 hours) the cells on the brain slices were formalin fixed, frozen, sectioned further,
and IHC stained for anti-GFP as a melanoma cell marker. (A) Cells plated with no treatment, (B)
cells plated after treatment with heparanase (50 ng/ml).
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Figure 4.2 Heparanase Invasion Assay Using a Brain Slice Model
Extent of invasion into brain slices by murine brain metastatic melanoma cells as shown using
quantitative analysis at 72 hours post implantation. The migration by GFP-expressing cells was
measured by the number of cells invading beyond the surface of the brain per unit of area.
Melanoma cells pre-treated with heparanase (50 ng/ml) had a greater number of cells invade into
the brain slice per unit area than did control cells without pre-treatment. Heparanase treated cells
sample (n = 75), Control group sample size (n = 100). Data were considered significant if
p < 0.05.
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and control cells (Figure 4.3). Statistical analysis of both the HPSE-1 treated and corresponding
control groups showed a good correlation between the number of cells invaded and the depth of
cell invasion. This correlation was further analyzed and determined to be a good predictive
model for overall cell invasion. Analysis of covariance was performed and showed a significant
difference of HPSE-1 invasiveness when compared to corresponding control groups (Table 1).
4.3.2 NFG Shows an Increase in Depth of Invasion
After treating the cell with NGF (50 ng/ml) and following their incubation (72 hours),
immunohistochemistry was performed to mark the invading tumor cells in order to correctly
distinguish the cancer cell from normal brain tissue. Upon analysis of the NGF invasion assay,
NGF influenced invasion in a completely different way. NGF-treated samples, when analyzed
for cell count, had fewer cells invade than untreated control groups (Figure 4.4). Conversely,
when analyzing the depth of tumor cell invasion into the brain tissue NGF had higher depth than
control groups (Figure 4.5). Statistical analysis showed a very good correlation between the
number of cells invaded and depth of cell invasion for the control groups; however, the NGF
treated groups had a poor correlation between cell number and depth of invasion. As a result, the
NGF treated group made a poor model for cell invasiveness based on the assumption that cell
number and depth correlate while the control group made for a strong predictive model.
Conversely, when analysis of covariance was performed, NGF treated samples and control
groups did not show a difference in invasiveness. NGF treatment groups showed a poor
correlation because they had fewer cells invade, but the cells that did invade invaded further,
which does not agree with the defined model.
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Figure 4.3 Invasion Depth in the Presence of Heparanase Using a Brain Slice Model
Depicting the depth of invasion into brain slices by murine brain metastatic melanoma cells as
shown using quantitative analysis at 72 hours post implantation. The extent of migration by
GFP-expressing cells was expressed by measuring the depth of the most invasive cells per brain
slice. Melanoma cells pre-treated with of heparanase (50 ng/ml) showed no difference from cell
without pre-treatment with regards to depth of invasion. Heparanase treated cells sample (n =
75), Control group sample size (n = 100). Data were considered significant if p < 0.05.
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Table 4.1 Statistical Analysis to Determine the Validity of Invasion Quantitation Methods

Cell
Treatment

Pearson
Correlation1

Regression
Analysis2

ANCOVA3

Tukey
Grouping4

Control

0.59430

0.3532

0.99901

A

Heparanase

0.59155

0.3499

0.86504

B

1

Pearson Correlation was to determine the correlation between the number of cells
invading and the depth of cell invasion.
2
Regression analysis was performed, showing R-square values, to determine the predictive
model for invasion.
3
Analysis of covariance was performed looking at heterogeneity of slopes.
4
Tukey’s grouping, designated by A and B, shows a significant difference between the
treatment groups. p < 0.05
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Figure 4.4 Nerve Growth Factor Invasion Assay Using a Brain Slice Model
The extent of invasion in brain slices by murine brain metastatic melanoma cells as shown using
quantitative analysis at 72 hours post implantation. The extent of migration by GFP-expressing
cell was measured by the number of cells invading beyond the surface of the brain per unit of
area. Melanoma cells pre-treated with NGF (50 ng/ml) showed no difference in the number of
cells invading than control cells without NGF pre-treatment. NGF treated cells sample (n = 90),
Control group sample size (n = 68). Data were considered significant if p < 0.05.
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Figure 4.5 The Depth of Invasion with Invasion Assays in the presence of NGF
Invasion into brain slices by murine brain metastatic melanoma cells as shown using quantitative
analysis at 72 hours post implantation. The extent of migration by GFP-expressing cells was
expressed by measuring the depth of the most invasive cells per brain slice. Melanoma cells pretreated with nerve growth (50 ng/ml) factor showed an increase in invasion when compared to
cells without pre-treatment with regards to depth of invasion. NGF treated cells sample (n = 98),
Control group sample size (n = 68). Data were considered significant if p < 0.05.
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However, these results are correlative to previous findings who have investigated metastasis.
NGF promotes tumor cell survival and aggressiveness in addition to its capabilities as a
differentiation factor (Marchetti et al., 1993; Marchetti et al., 1996; Marchetti et al., 2001;
Marchetti et al., 2004).
4.3.3 Melanoma Cells Show a Correlation Between HPSE-1 Expression and
Incubation Time
Immunohistoshemistry was performed on brain slice model OCT-embedded sections
which had B16B15b-GFP cells implanted on them and incubated for 2, 12, and 24 hours. Upon
staining for HPSE-1 with an anti-HPSE-1 polyclonal antibody, we observed a low level amount
of HPSE-1 staining on the B16B15b-GFP cells that had been implanted on the brain slice for
only 2 hours. Additionally, the cells that were incubated for 12 hours showed a definitive
increase in HPSE-1 staining and an increase in invasion. Finally, the 24 hour time point showed
the heaviest staining for HPSE-1 as well as the greatest amount of invasion (Figure 4.6).
4.4 Discussion
Heparanase, which is an enzyme critically involved in degrading and remodeling ECM
and basement membranes, has been shown to correlate with the metastatic potential of a variety
of tumor-derived cell lines (Nakajima et al., 1983; Nakajima et al., 1984; Nakajima et al., 1988;
Vlodavsky et al., 2001). Upon plating HPSE-1 treated brain-metastatic melanoma cells on brain
slices, we were expecting a large number of cells to invade very aggressively. However, the
HPSE-1 invasion assay had a high number of cells invade, but the cells didn’t invade deep into
the tissue. In fact, there was little difference between the HPSE-1-treated cells and the control
cells as to depth of invasion. This may be due to the fact that HPSE-1 degraded the basement
membrane of the brain slice, but did not actually stimulate the cells to a
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Figure 4.6 HPSE-1 Time Dependent Expression in Brain-Metastatic Melanoma Cells.
B16B15b-GFP cells were implanted on the brain slices and at 2 hours. (A,D), 12 hours. (B,E),
and 24 hours respectively. (C, F) post-implantation the experiments were stopped and IHC was
performed. (A, E, F) Nuclei stained by hematoxylin with an isotyped matched mouse
monoclonal antibody used as the primary antibody for a negative control for IHC staining. (A,
B, C) Hematoxylin staining with anti-HPSE-1 PAb showing increased HPSE-1 expression at
increasing time points. Digital images were produced on an Axioplan microscope with
Advanced Spot imaging program (Diagnostic Instruments Inc., Sterling Heights, MI) with 20x
objective using identical conditions for all photographs.
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more aggressive metastatic state. The result from this would be the cells migrating into the area
of the brain that the HPSE-1 degraded away, but the cells were not aggressive enough to actively
invade farther into the tissue.
The NGF receptor (p75NTR) is abundantly expressed in many melanoma tumors, and
p75NTR is especially over-expressed during the later stages of melanoma progression (Marchetti,
1993). It is known that malignant melanoma develops from cells undergoing an uncontrolled cell
survival, growth, and proliferation to a neoplastic setting. This response is dependent upon these
cells having an enhanced sensitivity to either autocrine or paracrine growth factors (Nicolson,
1993). Through responsiveness to these growth factors, melanoma cells can become clonaly
dominant within a tumor. This is what makes the paracrine factor NGF such an interesting
molecule because it has the ability to influence cancer cells to progress into malignant
aggressiveness and survivability. However, for NGF to be able to promote this effect, there has
to be a high concentration of the p75NTR present on the cell surface. It is this p75NTR that makes
the results of our invasion assay from the brain slice model of interest. NGF treated cells had a
lower number of cells invading over time; however, cells that invaded migrated to a greater
depth. This could mean that only a few of the cells overexpressed p75NTR. Consequently, when
the NGF was added to our brain slice models only a few of the cells became clonally dominant,
but the few that invaded did so aggressively (Marchetti et al., 1993; Marchetti et al., 2004; Walch
et al., 1999).
The orthotopic brain slice model can present an in vitro model of the central nervous
system in which neuronal architecture can be maintained. This model would create a co-culture
between the melanoma cells and the brain tissue environment that allows a more realistic growth
environment yet still being rather easy to manipulate treatment. First, it provides the ability to
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analyze processes at the cell and molecular level while the cells are growing in a viable
environment. Second, it allows the opportunity to run an invasion assay without having to add
chemoattractants to the assay (Stoppini et al., 1991). Third, having the brain slice model for brain
metastatic melanoma is especially helpful because it is thought that metastasis is dependent on
certain host tissue properties, particularly the host microenvironment. For these reasons, this
model is of considerable use in the future research of brain metastatic melanoma. This model has
been previously used in studying mechanisms of invasion in glioma cells and astrocytoma cells
(Jung et al., 2001; Matzner et al., 1992; Ohnishi et al., 1998; Yoshida et al., 2002). This novel
model has shown that brain derived neurotrophic factor mediates activity-dependent dendritic
growth in neocortical interneurons in developing organotypic cultures (Jin et al., 2003). The
othotopic brain slice model has proven useful in both the study of physiological and
pathophysiological developmental processes.
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CHAPTER 5: SUMMARY AND CONCLUSIONS
The first part of our studies was focused on in vivo experimentation and in looking at HPSE-1
expression from tumors that metastasized to the lung. Since metastatic melanoma cells express
high levels of HSPG, and their tumors grow highly vascularized, we analyzed melanoma tissue
specimens for HPSE-1 expression from experimental animals as well as from patients. The
results from these analyses demonstrated that HPSE-1 mRNA is significantly elevated in
metastatic melanoma when compared to adjacent lung tissue. We showed that there were
increased levels of HPSE-1 protein expression in metastatic melanoma clinical specimens while
primary tumors result in low level HPSE-1 protein expression. Another finding was that the
presence of HPSE-1 appeared to be more concentrated around blood vessels and vascular regions
in brain-metastatic melanoma specimens, a relevant finding since heparanase in known to be
involved in angiogenesis.
Since we had already shown that HPSE-1 expression is upregulated in tumor tissue when
compared to normal corresponding tissue, we wanted to prove mechanistically that HPSE-1
promotes invasion in in vivo-like conditions. Therefore, the objective of the second part of this
project was to establish an organotypic culture system that can be of considerable usefulness in
studying the process of brain-metastatic melanoma invasion. First, this model provides a better
representation of the ECM molecules normally encountered by invading melanoma cells.
Second, it gives the ability to monitor tumor invasion at both quantitative and qualitative levels.
In fact, brain-metastatic melanoma cells showed a significant increase in invasion when treated
with HPSE-1 versus untreated cells. Additionally, melanoma cells plated on these organotypic
cultures showed differential expression of HPSE-1 at the protein level during a time-course
experiment.
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Finally, this model is important because it can be used to determine mechanisms in
cancer invasion and metastasis. First, it can be used to determine in vivo biological effects in
conjunction with approaches that selectively block the expression of molecules implicated in
cellular invasion. Furthermore, with this model, biological effects are quantifiable, hence it can
be used to determine therapeutic efficiency.
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